SCHEMBL5032370

SCHEMBL5032370

CCC(Nc1nc(NCC2CCCCC2)nc(Nc2ccc(OC)c(F)c2)n1)C1CCNC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GALR1 P47211 4/20 0.55
CDK1 P06493 2/20 0.39
CDK4 P11802 2/20 0.39
CCNB1 P14635 2/20 0.39
CCND1 P24385 2/20 0.39
CCNE1 P24864 2/20 0.39
CDK2 P24941 2/20 0.39
GALR2 O43603 4/20 0.38
METAP2 P50579 1/20 0.37
PTK2 Q05397 3/20 0.36
SOS1 Q07889 1/20 0.36
KDM1A O60341 2/20 0.36
BCL6 P41182 1/20 0.36
ENO1 P06733 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
EHMT2 Q96KQ7 1/20 0.35
EHMT1 Q9H9B1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839616 0.87 GALR1 (0.55) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL6013860 0.87 GALR1 (0.55) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL5031255 0.87 GALR1 (0.55) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL5036365 0.87 GALR1 (0.55) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL4837841 0.87 GALR1 (0.55) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL4836390 0.87 GALR1 (0.55) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL6013830 0.87 GALR1 (0.55) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL5029188 0.86 GALR1 (0.53) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL5031363 0.83 GALR1 (0.50) GALR1CDK1CDK4CCNB1CCND1
SCHEMBL6428019 0.81 FLT3 (0.40) GALR1CDK1CCNB1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238692-B2 Medical devices employing triazine compounds and compositions thereof REDDY US THERAPEUTICS, INC. (US) 2007-07-03 US claimed
US-7169785-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-01-30 US claimed
WO-2004026844-A9 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS REDDY US THERAPEUTICS INC (US) 2004-11-11 WO claimed
US-20040209882-A1 Methods and compositions of novel triazine compounds DR. REDDY'S LABORATORIES LTD. (IN) 2004-10-21 US claimed
US-7332488-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2008-02-19 US disclosed
US-7238692-B2 Medical devices employing triazine compounds and compositions thereof REDDY US THERAPEUTICS, INC. (US) 2007-07-03 US disclosed
US-20050124619-A1 Medical devices employing triazine compounds and compositions thereof DR. REDDY'S LABORATORIES LTD. (IN) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209882-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS GALR1 961/4885CDK1 655/4885CDK4 845/4885
US-20050124619-A1 Medical devices employing triazine compounds and compositions thereof PTGIS, AREG, TGFB1 GALR1 1159/4885CDK1 1388/4885CDK4 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.